In the Margins

Sequoia Fund's Valeant bet highlights concentration risks

November 2, 2015

By The Wall Street Journal

Concentrated bets on individual stocks raise issues for mutual funds and their investors—a matter highlighted last week at Sequoia Fund, one of the biggest investors in controversial drug maker Valeant Pharmaceuticals International Inc. Placing outsize bets on well-chosen stocks can lead to strong performance, but concentration increases the riskiness of a fund and raises questions about how much is too much. Read the original story from The Wall Street Journal.

 

 

Most Read

Top of the Agenda - Governance
Recruiting in the time of coronavirus

Mutual fund boards seem well on their way to mastering the art of conducting business virtually, but one area that may still be a challenge during ...

Top of the Agenda - Legal
Greene, Baris join Sidley Austin funds group

Mutual fund industry lawyers Nathan Greene and Jay Baris today have joined Sidley Austin's LLP's New York office as partners in the Investment Funds group. Both ...